Liver Cancer

Liver cancer refers to malignancies that originate in the liver itself — as opposed to cancers that have spread to the liver from elsewhere (metastatic cancer). The most common type is hepatocellular carcinoma (HCC), which accounts for approximately 75–85% of primary liver cancers and arises from hepatocytes, the main functional liver cells. Other types include intrahepatic cholangiocarcinoma (arising from bile duct cells within the liver), fibrolamellar carcinoma (a distinct HCC variant in young patients without cirrhosis), hepatoblastoma (the most common childhood liver tumor), and hepatic angiosarcoma (a rare vascular malignancy).

Each type is managed differently, so confirming the exact type — through imaging, serum markers, and biopsy when needed — is the essential first step before any treatment discussion.

Early liver cancer — particularly HCC — is often asymptomatic, which is one reason why regular surveillance of high-risk individuals (those with cirrhosis or chronic hepatitis B) is so important. Symptoms that may appear as the disease develops include dull pain or discomfort in the right upper abdomen, unexplained weight loss, loss of appetite, fatigue, abdominal swelling, and nausea.

In patients with known chronic liver disease, any worsening of existing symptoms — new or worsening ascites (fluid in the abdomen), jaundice, or episodes of confusion — should prompt urgent evaluation, as these may indicate either liver cancer development or decompensation of underlying liver disease. An elevated AFP on routine surveillance blood work is an important signal to investigate further with imaging.

For hepatocellular carcinoma specifically, a biopsy is often not required if the imaging is sufficiently characteristic. In a patient with established cirrhosis, a liver lesion larger than 1 cm that shows arterial-phase enhancement with washout on contrast-enhanced CT or MRI meets internationally accepted diagnostic criteria for HCC (LI-RADS 5). This avoids the small risk of needle track seeding that biopsy carries.

However, biopsy is required when imaging is atypical, when the patient does not have established cirrhosis, or when the tumor type is uncertain. For intrahepatic cholangiocarcinoma, angiosarcoma, and other non-HCC liver tumors, tissue confirmation is always necessary — and for cholangiocarcinoma, the biopsy specimen should also undergo molecular profiling to identify actionable alterations.

The Child-Pugh score is a clinical scoring system that measures how well the liver is functioning — based on bilirubin level, albumin level, prothrombin time, degree of ascites, and presence of hepatic encephalopathy. Patients are classified as Child-Pugh A (well-compensated), B (moderate impairment), or C (severe impairment).

For liver cancer — especially HCC — Child-Pugh class is as important as tumor stage in determining which treatments are possible. Child-Pugh A patients qualify for the full range of options: surgery, locoregional therapy, and systemic treatment including immunotherapy. Child-Pugh B patients have more limited options, and many systemic agents are not safe or effective when liver function is significantly impaired. Child-Pugh C patients are generally limited to supportive care or transplant evaluation. Understanding your Child-Pugh score is therefore essential context for any treatment discussion.

HCC treatment depends on tumor stage, number and size of tumors, vascular invasion, presence of metastases, and underlying liver function. For early-stage disease (BCLC 0-A), curative options include surgical resection, liver transplantation, or thermal ablation (radiofrequency or microwave ablation). For intermediate-stage disease (BCLC-B, multinodular without metastases), locoregional therapy with TACE or TARE is standard. For advanced disease (BCLC-C, with vascular invasion or metastases), systemic therapy is required — the current first-line standard is atezolizumab plus bevacizumab, with lenvatinib and sorafenib as alternatives.

Second-line systemic options include regorafenib, cabozantinib, ramucirumab (for AFP ≥400), and pembrolizumab. Liver transplantation is curative and simultaneously replaces the disease-prone cirrhotic liver — if you have HCC and have not been evaluated for transplant eligibility, this warrants a specialist discussion.

Yes — comprehensive molecular profiling (NGS panel) is now considered standard of care for all patients with advanced intrahepatic cholangiocarcinoma. This is because several approved targeted therapies are available for specific molecular subgroups: pemigatinib and futibatinib for FGFR2 fusion-positive tumors, ivosidenib for IDH1-mutant tumors, and pembrolizumab for MSI-H tumors. BRAF V600E mutations, HER2 amplification, and NTRK fusions are also actionable in some settings.

The critical point is that molecular testing should be done at the time of diagnosis of advanced disease — not after progression on first-line chemotherapy — so that results are available when they are needed for second-line treatment selection. If you have not had NGS panel testing, this should be discussed with your oncologist or a specialist center urgently.

TACE (transarterial chemoembolization) and TARE (transarterial radioembolization, also called SIRT — selective internal radiation therapy) are both catheter-based procedures performed by interventional radiologists that deliver treatment directly to liver tumors via the hepatic artery, exploiting the fact that liver tumors are supplied predominantly by arterial blood while the surrounding liver receives most of its supply from the portal vein.

TACE delivers chemotherapy (typically doxorubicin) combined with embolic particles that block blood flow, causing tumor ischemia. TARE delivers radioactive Yttrium-90 microspheres that emit localized radiation within the tumor. Both are used for intermediate-stage HCC. TARE tends to have lower rates of post-embolization syndrome (the flu-like illness following TACE) and may be preferable in patients with mild portal vein involvement. The choice between them depends on tumor anatomy, liver function, and institutional expertise. Not all centers offer both procedures.

Yes — China has one of the highest liver cancer burdens in the world, which has driven the development of a large and sophisticated liver cancer research infrastructure. Several advanced treatment programs are primarily accessible through Chinese specialist centers, including GPC3-targeted CAR-T cell therapy for HCC (in phase II development), novel immunotherapy combinations not yet globally approved, and locoregional therapy combinations under investigation.

Additionally, some systemic agents approved in China for liver cancer may not yet be available in other countries, and clinical trial enrollment at centers such as CAMS, Sun Yat-sen University Cancer Center, and others provides access to cutting-edge programs. CancerFax has experience coordinating patient evaluation and enrollment at specialist liver cancer centers in China and can assist with report review, translation, and center liaison.

Yes. CancerFax supports liver cancer patients and families through the full treatment navigation process. We begin with a thorough review of your imaging reports, liver function assessments (Child-Pugh, AFP, LFTs), biopsy results, and molecular profiling data to establish your exact cancer type, disease stage, and liver functional reserve — the three pillars of treatment planning in liver cancer.

Based on this review, we identify which treatment approaches apply — from locoregional procedures (TACE, TARE, ablation) to systemic immunotherapy and targeted therapy — and which advanced options may be relevant, including FGFR or IDH1-targeted therapy for cholangiocarcinoma, GPC3 CAR-T programs for HCC in China, and clinical trials at specialist centers in India, China, South Korea, and globally. We coordinate second opinion consultations with specialist hepatic oncologists and HPB surgeons, and support international treatment navigation for patients exploring options abroad. Share your reports to get started.